{"nctId":"NCT02997501","briefTitle":"T790M Plasma Testing Methodology Comparison and Clinical Validation","startDateStruct":{"date":"2016-12-23","type":"ACTUAL"},"conditions":["Lung Cancer"],"count":256,"armGroups":[{"label":"AZD9291","type":"EXPERIMENTAL","interventionNames":["Procedure: T790M+ Testing","Procedure: Baseline Visit Blood & Urine Testing","Procedure: Baseline ECG","Procedure: Visual Slit-Lamp Testing","Drug: AZD9291 Dosing","Procedure: Plasma AZD9291 testing"]}],"interventions":[{"name":"T790M+ Testing","otherNames":[]},{"name":"Baseline Visit Blood & Urine Testing","otherNames":[]},{"name":"Baseline ECG","otherNames":[]},{"name":"Visual Slit-Lamp Testing","otherNames":[]},{"name":"AZD9291 Dosing","otherNames":[]},{"name":"Plasma AZD9291 testing","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Provision of informed consent prior to any study specific procedures.\n2. Adults (according to China regulations for age of majority)\n3. Histological or cytological confirmed locally advanced NSCLC (stage IIIB) or metastatic (stage IV) NSCLC, not amenable to curative surgery or radiotherapy.\n4. Patients who have progressed following prior therapy with an EGFR-TKI agent.\n\nExclusion Criteria:\n\n1. Patients who disagree to participate this study.\n2. Patients whose medical objection was recorded to use the existing data from medical practice for scientific research.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"130 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Concordance","description":"To evaluate concordance of T790M plasma mutation testing between the Cobas test and each of other platforms: Super-ARMS, digital PCR or NGS.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.8","spread":null}]}]}]},{"type":"PRIMARY","title":"PFS Using Investigator Assessments According to RECIST v1.1","description":"To assess the efficacy of AZD9291 monotherapy by assessment of PFS in adult patients with advanced or metastatic NSCLC, who have received prior EGFR- TKI therapy and are T790M mutation positive detected by any one of the four plasma testing platforms. PFS was defined using Response Evaluation Criteria In Solid Tumors version 1.1(RECIST v1.1).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Testing Sensitivity, Specificity, PPV, NPV","description":"To evaluate the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of Super-ARMS/digital PCR/NGS by using Cobas as the reference.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate (ORR)","description":"To assess the efficacy of AZD9291 monotherapy by assessment of ORR in adult patients who have received prior EGFR-TKI therapy and are EGFR T790M mutation positive detected by any one of the four plasma testing platforms. ORR is defined as the percentage of patients with measurable disease with at least 1 visit response of CR or PR. Data obtained until progression or last evaluable assessment in the absence of progression will be included in the assessment of ORR.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.1","spread":null}]}]}]},{"type":"SECONDARY","title":"75% OS Duration","description":"To assess the efficacy of AZD9291 monotherapy by assessment of overall survival (OS) in adult patients who have received prior EGFR-TKI therapy and are EGFR T790M mutation positive detected by any one of the four plasma testing platforms. 75% OS duration was calculated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":0},"commonTop":[]}}}